Literature DB >> 9619167

Biliary dyskinesia: natural history and surgical results.

R M Goncalves1, J A Harris, D E Rivera.   

Abstract

Patients with biliary dyskinesia have symptoms consistent with biliary colic and an abnormal gallbladder ejection fraction (GEF) in the absence of cholelithiasis. Cholecystokinin hepatobiliary scan quantifies gallbladder function and may assist in selecting patients with acalculous biliary pain who would benefit from cholecystectomy. Seventy-eight patients with an abnormal GEF (< 35%) on cholecystokinin hepatobiliary scan without cholelithiasis were studied retrospectively. Patients were divided into groups based on diagnosis and treatment. In Group I, the patients who underwent cholecystectomy, 80 per cent (35 of 44) had complete symptomatic resolution whereas the remaining 20 per cent (9 of 44) had symptomatic improvement. Pathology reports demonstrated chronic cholecystitis in 95 per cent of specimens. Group II were patients with symptoms attributable to biliary dyskinesia, but did not undergo cholecystectomy. Persistence of symptoms was noted in 75 per cent (18 of 24) of patients whereas 25 per cent (6 of 24) had symptomatic resolution without any treatment. Group III consisted of patients with an abnormal ejection fraction who had improvement of symptoms after treatment for an alternative diagnosis (n = 10). These findings suggest that an abnormal ejection fraction does not always indicate gallbladder disease. Alternative diagnoses must be investigated and treated. Patients with persistent biliary type symptoms in combination with an abnormal GEF in the absence of other attributable causes can expect a favorable response to cholecystectomy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619167

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  17 in total

Review 1.  Controversies concerning pathophysiology and management of acalculous biliary-type abdominal pain.

Authors:  Amit Rastogi; Adam Slivka; Arthur James Moser; Arnold Wald
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

2.  Evaluation of gastrointestinal pathology and treatment in children with suspected biliary dyskinesia.

Authors:  Wikrom Karnsakul; Richard Vaughan; Tarun Kumar; Stacey Gillespie; Kathryn Skitarelic
Journal:  Pediatr Surg Int       Date:  2011-06-25       Impact factor: 1.827

Review 3.  Cholecystectomy for biliary dyskinesia: how did we get there?

Authors:  Klaus Bielefeldt; Shreyas Saligram; Susan L Zickmund; Anwar Dudekula; Mojtaba Olyaee; Dhiraj Yadav
Journal:  Dig Dis Sci       Date:  2014-09-06       Impact factor: 3.199

4.  Biliary dyskinesia: how effective is cholecystectomy?

Authors:  Vikas Singhal; Patrick Szeto; Heather Norman; Nan Walsh; Burt Cagir; Thomas J VanderMeer
Journal:  J Gastrointest Surg       Date:  2011-11-01       Impact factor: 3.452

5.  Biliary dyskinesia: a potentially unrecognized cause of abdominal pain in children.

Authors:  Brendan T Campbell; Nathan P Narasimhan; Eustace S Golladay; Ronald B Hirschl
Journal:  Pediatr Surg Int       Date:  2004-08-18       Impact factor: 1.827

Review 6.  Biliary dyskinesia in pediatrics.

Authors:  Grzegorz Telega
Journal:  Curr Gastroenterol Rep       Date:  2006-04

7.  Gallbladder ejection fraction and symptom outcome in patients with acalculous biliary-like pain.

Authors:  Nuri Ozden; John K DiBaise
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

Review 8.  Biliary dyskinesia in the pediatric patient.

Authors:  Michael S Halata; Stuart H Berezin
Journal:  Curr Gastroenterol Rep       Date:  2008-06

Review 9.  [Acute biliary colic. Etiology, diagnosis and therapy].

Authors:  Birgit Terjung; M Neubrand; T Sauerbruch
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

10.  The role of (99m)technetium-labelled hepato imino diacetic acid (HIDA) scan in the management of biliary pain.

Authors:  K Riyad; C R Chalmers; A Aldouri; S Fraser; K Menon; P J Robinson; G J Toogood
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.